Internal Med Medical News about Paclitaxel

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Efficacies of the new Paclitaxel-eluting Coroflex PleaseTM Stent in percutaneous coronary intervention; comparison of efficacy between Coroflex PleaseTM and TaxusTM (ECO-PLEASANT) trial: study rationale and design
Trials, 10/26/09

Seo JB et al. – The ECO–PLEASANT trial is the study not yet performed to directly compare the efficacy and safety of the Coroflex PleaseTM versus Taxus LiberteTM stent. On the basis of this trial, we will be able to find out whether the Coroflex PleaseTM stent is non–inferior to Taxus LiberteTM stent or not.

<< Previous
Gender differences in professional development of healthcare...

Next >>
Blood Pressure Control Determines Improvement in Diastolic...

A phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma
Journal of Clinical Oncology, 10/19/09 Relevance Score: 94%

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic NSCLC
Annals of Oncology, 10/19/09 Relevance Score: 92%

Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Annals of Oncology, 11/10/09 Relevance Score: 89%

Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
Journal of Clinical Oncology, 10/29/09 Relevance Score: 88%

Weekly paclitaxel and cisplatin in the treatment of elderly advanced non-small cell lung cancer
Chinese Journal of Lung Cancer, 10/27/09 Relevance Score: 88%